Tara Nazareth

Costs and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumonia

Background Patients with chronic obstructive pulmonary disease (COPD) are at increased risk for lung infections and other pathologies (eg, pneumonia); however, few studies have evaluated the impact of pneumonia on health care resource utilization and costs in this population. The purpose of this study was to estimate health care resource utilization and costs among COPD patients with newly acquired pneumonia compared to those without pneumonia. Methods A retrospective claims analysis using Truven MarketScan® Commercial and Medicare databases was conducted. COPD patients with and without newly acquired pneumonia diagnosed between January 1, 2004 and September 30, 2011 were identified. Propensity score matching was used to create a 1:1 matched cohort. Patient demographics, comorbidities (measured by Charlson Comorbidity Index), and medication use were evaluated before and after matching. Health care resource utilization (ie, hospitalizations, emergency room [ER] and outpatient visits), and associated health care costs were assessed during the 12-month follow-up. Logistic regression was conducted to evaluate the risk of hospitalization and ER visits, and gamma regression models and two-part models compared health care costs between groups after matching. Results In the baseline cohort (N=467,578), patients with newly acquired pneumonia were older (mean age: 70 versus [vs] 63 years) and had higher Charlson Comorbidity Index scores (3.3 vs 2.6) than patients without pneumonia. After propensity score matching, the pneumonia cohort was nine times more likely to have a hospitalization (odds ratio; 95% confidence intervals [CI] =9.2; 8.9, 9.4) and four times more likely to have an ER visit (odds ratio; 95% CI =4.4; 4.3, 4.5) over the 12-month follow-up period compared to the control cohort. The estimated 12-month mean hospitalization costs (

Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective

14,353 [95% CI:

Physician-Patient Concordance in Pharmacological Management of Patients with COPD

14,037–

Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders

14,690]), outpatient costs (

Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review.

6,891 [95% CI:

Outcomes-Based Pricing And Reimbursement Arrangements For Pharmaceutical Products In The Us And Eu-5: Payer And Manufacturer Experience And Outlook

6,706–

Persistence with Fingolimod Versus Dimethyl Fumarate in Patients with Multiple Sclerosis: Retrospective Analysis of us Open-Source Pharmacy Data.

7,070]), and prescription drug costs (

Impact of Omalizumab On All-Cause and Asthma-Related Health Care Resource Utilisation in Patients With Moderate or Severe Persistent Asthma.

1,104 [95% CI:

The Economic Burden of Moderate-to-Severe Multiple Sclerosis Relapse in the United States: Findings from a Systematic Literature Review (P3.402)

1,054–

OUTCOMES-BASED ARRANGEMENTS IN VALUE-BASED CARE: AN ENGAGEMENT FRAMEWORK

1,142]) were higher in the pneumonia cohort than in the control cohort. Conclusion This study demonstrated elevated health care resource use and costs in patients with COPD after acquiring pneumonia compared to those without pneumonia.